Trial Profile
Efficacy and Safety of Granulocyte-colony Stimulating Factor in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid: A Randomized, Double-blind, Placebo-controlled, Nationwide Multi-center Study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2022
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary) ; Methylprednisolone; Prednisolone
- Indications Alcoholic hepatitis
- Focus Proof of concept; Therapeutic Use
- Acronyms GraCiAH
- 04 Aug 2022 Status changed from recruiting to discontinued due to failure to recruit eligible patients.
- 02 Nov 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 02 Nov 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2022.